Abbott

Global healthcare company Abbott on Tuesday announced the launch of its drug eluting stent in the country which it claimed would be helpful in treating complex heart blockages. The new device, XIENCE Skypoint, is designed to be more flexible, easier to guide through the heart's arteries, including large vessels, and better suited for treating complex heart blockages, the company said in a statement. "The launch of XIENCE Skypoint in India represents an advancement for doctors treating cardiovascular disease, which remains a leading cause of mortality in India," Tushar Sharma, general manager for Abbott's vascular business in India and South Asia said. Many patients develop severe blockages earlier in life due to rising hypertension, diabetes, cholesterol, and lifestyle risks. "This makes it essential to support doctors with stents that can safely reach difficult areas and treat a wide range of blockages," Sharma stated. XIENCE Skypoint brings improvements with precision and ...

Abbott will commercialise Extensior, a second semaglutide brand of Ozempic in India, as part of Novo Nordisk's strategy to expand access amid rising demand and looming patent expiry

Global healthcare company Abbott on Monday announced the launch of a dual-chamber leadless pacemaker system, which will help the heart beat properly without wires or surgical pockets used in traditional pacemakers. Pacemakers help keep the heart beating at a healthy pace, especially in the case of bradycardia, a condition where the heart beats too slowly. In a statement, Abbott said its implant-to-implant device technology enables wireless communication and synchronisation between two leadless pacemakers, which are smaller than an AAA battery. Until recently, leadless pacemakers could only support one chamber of the heart, because getting two separate devices to work together in sync was a major challenge. "As leadless pacing technology has evolved, we've built upon our AVEIR VR single-chamber platform to expand the benefits of leadless pacing to far more people and provide additional treatment options to patients," said Ajay Singh Chauhan, General Manager for Abbott's cardiac rhyt

Abbott to distribute MSD's sitagliptin portfolio-Januvia, Janumet, Janumet XR-in India, targeting deeper reach in the ₹950-1,000 crore diabetes drug segment

Abbott India's profit jumped 24.1 per cent to Rs 287.1 crore in the March quarter of FY24 (Q4FY24), from Rs 231.4 crore in the March quarter of FY23 (Q4FY23)

In its letter, the DCGI warned that Digene may be unsafe and its use may result in adverse reaction

The DCGI has cautioned against the consumption of Abbott's antacid Digene gel citing safety concerns, even as the US-based drugmaker recalled several batches of the medicine manufactured at its Goa facility. According to a letter by the Drugs Controller General of India (DCGI), it was reported on August 9 that a bottle of Digene Gel (mint flavour), batch no 51030307, used by customers was of regular taste (sweet) and light pink in colour whereas another bottle of the same batch was of white colour with bitter taste and pungent odour as per a complaint. "Accordingly, M/s Abbott India Limited, Verna Industrial Estate, Salcette, Goa- vide letter dated August 11, 2023, informed DCGI office for voluntary recall of impugned product Digene Mint flavour batch no 51030307 and Digene Gel orange having batch no 50035107, 50035207, 50035307, 50035407 and voluntary stopped production of all variants of Digene Gel manufactured at their Goa facility," the DCGI letter stated. Further, Abbott India

Abbott's diagnostic sales came in at $2.3 billion in the quarter, in line with analysts' average estimates.

Thyronorm has no quality issue, mislabeled batch was invoiced in Madhya Pradesh and Telangana: Company

US 10-year Treasury yield at highest since July 2008; Netflix jumps after reversing customer losses; P&G, Travelers post upbeat earnings; PHLX Housing Index falls 3% on weak US housing data

Analysts expect double-digit growth for pharma major even if Q1 disappointed

TNMSC Managing Director Deepak Jacob said the step was taken after a complaint from Paris Legal Cell in Chennai

The Defense Production Act order requires suppliers of formula manufacturers to fulfil orders from those companies before other customers, in an effort to eliminate production bottlenecks

The shortage stems from a February recall by Abbott that exacerbated ongoing supply chain disruptions among formula makers, leaving fewer options on stores shelves across much of the country

Abbott on Tuesday said it has tied up with health-tech firms like BeatO, Sugar.fit, PharmEasy, GOQii, 1MG and Zyla for diabetes care

The two leaders emphasised that enhanced economic cooperation between India and Australia would help the two countries

(Reuters) -Abbott Laboratories' quarterly profit more than doubled on Thursday, due to strength in its diagnostics business and a rebound in medical device sales.

Firm expects demand from both, institutions and retail consumers, will import kits in 4-pack sizes from Korean plant; Test linked with NAVICA app which uploads results on ICMR website

The device is particularly useful for tiny babies who may not be able to undergo surgery to repair their hearts

Abbott said it is already in the process of delivering antibody tests to leading government and private hospitals and labs across different states